# US 2008/0188487 A1 · 5-amido-(1h-indol-2-yl)-piperazin-1-yl-methanone derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188487 A1
- Document ID: US20080188487A1
- Status: Published application
- Kind: A1
- Application number: 12/020,637
- Filed: 2008-01-28
- Published: 2008-08-07
- Earliest claimed: 2007-02-07
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Matthias Nettekoven; Jean-Marc Plancher; Hans Richter; Olivier Roche; Sven Taylor
- Web page: https://patentgrep.com/patent/US20080188487A1

## CPC

- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula I wherein A, G and R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is C(O) or S(O)2;
R1 is selected from the group consisting of:
(1) lower alkyl,
(2) lower alkoxy,
(3) cycloalkyl,
(4) lower cycloalkylalkyl,
(5) lower halogenalkyl,
(6) phenyl unsubstituted or substituted with one to three substituents independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, lower halogenalkyl and cyano, and
(7) —NR4R5, wherein R4 and R5 independently from each other are selected from the group consisting of lower alkyl, cycloalkyl, lower cycloalkylalkyl, lower halogenalkyl and lower phenylalkyl, or alternatively, R4 and R5 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom of nitrogen, oxygen or sulfur;
R2 is selected from the group consisting of:
(1) hydrogen,
(2) lower alkyl,
(3) cycloalkyl,
(4) lower cycloalkylalkyl,
(5) lower hydroxyalkyl,
(6) lower alkoxyalkyl,
(7) lower halogenalkyl,
(8) lower cyanoalkyl,
(9) lower alkylsulfonyl,
(10) lower alkanoyl,
(11) phenylsulfonyl wherein the phenyl ring may be unsubstituted or substituted with one to three substituents independently selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower halogenalkoxy and lower hydroxyalkyl,
(12) phenyl unsubstituted or substituted with one to three substituents independently selected from the group consisting of lower alkyl, halogen, cyano, morpholinyl, lower alkoxy, lower alkoxycarbonyl, lower halogenalkyl, lower halogenalkoxy, lower hydroxyalkyl, lower alkylsulfonyl and lower alkylsulfonylamino,
(13) benzodioxolyl,
(14) lower phenylalkyl, wherein the phenyl ring may be unsubstituted or substituted with one to three substituents independently selected from the group consisting of lower alkyl, halogen, cyano, morpholinyl, lower alkoxy, lower alkoxycarbonyl, lower halogenalkyl, lower halogenalkoxy, lower hydroxyalkyl, lower alkylsulfonyl and lower alkylsulfonylamino, and
(15) heteroaryl unsubstituted or substituted with one or two substituents independently selected from the group consisting of lower alkyl, lower alkoxy, cyano, morpholinyl and halogen;
R3 is hydrogen, halogen or methyl;
G is either G1 or G2:
wherein:
R6 is lower alkyl, cycloalkyl, lower cycloalkylalkyl or a heterocyclic ring containing oxygen, and R7 is hydrogen; or alternatively R6 and R7 together are —(CH2)m—, wherein m is 3 or 4, and are bonded to each other to form a ring together with the carbon or nitrogen atom to which they are attached;
n is 1 or 2;
p is 1 or 2;
R8 is hydrogen or lower heterocyclylalkyl;
R9 and R10 independently from each other are hydrogen or —NR11R12; and
R11 and R12 independently from each other are lower alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring optionally containing a further heteroatom of nitrogen, oxygen or sulfur.

### Claim 2 (depends on 1)

A compound of claim 1, wherein A is S(O)2.

### Claim 3 (depends on 1)

A compound of claim 1, wherein A is C(O).

### Claim 4 (depends on 1)

A compound of claim 1, wherein R1 is selected from the group consisting of:
(1) lower alkyl,
(2) lower alkoxy,
(3) cycloalkyl,
(4) phenyl unsubstituted or substituted with one to three substituents independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, lower halogenalkyl and cyano, and
(5) —NR4R5, wherein R4 and R5 independently from each other are selected from the group consisting of lower alkyl, cycloalkyl, lower cycloalkylalkyl, lower halogenalkyl and lower phenylalkyl, or alternatively, R4 and R5 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom of nitrogen, oxygen or sulfur.

### Claim 5 (depends on 1)

A compound of claim 1, wherein R1 is lower alkyl, cycloalkyl, or phenyl.

### Claim 6 (depends on 1)

A compound of claim 1, wherein R1 is lower alkyl or cycloalkyl.

### Claim 7 (depends on 1)

A compound of claim 1, wherein R1 is —NR4R5, wherein R4 and R5 independently from each other are lower alkyl or wherein R4 and R5 together with the nitrogen atom they are attached to form a piperidine ring.

### Claim 8 (depends on 1)

A compound of claim 1, wherein R1 is lower alkoxy.

### Claim 9 (depends on 1)

A compound of claim 1, wherein R2 is selected from the group consisting of:
(1) hydrogen,
(2) lower alkyl,
(3) cycloalkyl,
(4) lower cycloalkylalkyl,
(5) lower halogenalkyl,
(6) phenyl unsubstituted or substituted with one to three substituents independently selected from the group consisting of lower alkyl, halogen, cyano, morpholinyl, lower alkoxy, lower alkoxycarbonyl, lower halogenalkyl, lower halogenalkoxy, lower hydroxyalkyl, lower alkylsulfonyl and lower alkylsulfonylamino, and
(7) pyridyl unsubstituted or substituted with one or two substituents independently selected from the group consisting of lower alkyl, lower alkoxy, cyano, morpholinyl and halogen.

### Claim 10 (depends on 1)

A compound of claim 1, wherein R2 is hydrogen.

### Claim 11 (depends on 1)

A compound of claim 1, wherein R2 is lower alkyl.

### Claim 12 (depends on 1)

A compound of claim 1, wherein R2 is phenyl unsubstituted or substituted with one to three substituents independently selected from the group consisting of lower alkyl, halogen and lower halogenalkyl.

### Claim 13 (depends on 1)

A compound of claim 1, wherein R2 is pyridyl which is unsubstituted or substituted with one or two substituents independently selected from the group consisting of lower alkyl and halogen.

### Claim 14 (depends on 1)

A compound of claim 1, wherein R3 is hydrogen.

### Claim 15 (depends on 1)

A compound of claim 1, wherein G is
wherein R6 is lower alkyl, cycloalkyl, lower cycloalkylalkyl or a heterocyclic ring containing oxygen, R7 is hydrogen, and n is 1 or 2.

### Claim 16 (depends on 1)

A compound of claim 1, wherein R6 is lower alkyl, cycloalkyl or tetrahydropyranyl.

### Claim 17 (depends on 1)

A compound of claim 1, wherein R6 is isopropyl.

### Claim 18 (depends on 1)

A compound of claim 1, wherein n is 1.

### Claim 19 (depends on 1)

A compound of claim 1, wherein n is 2.

### Claim 20 (depends on 1)

A compound of claim 1, wherein G is
wherein:
p is 1 or 2;
R8 is hydrogen or lower heterocyclylalkyl;
R9 and R10 independently from each other are hydrogen or —NR11R12; and
R11 and R12 independently from each other are lower alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring optionally containing a further heteroatom of nitrogen, oxygen or sulfur.

### Claim 21 (depends on 1)

A compound of claim 1 selected from the group consisting of:
[1-(2-chloro-pyridin-4-yl)-5-(4-isopropyl-piperazine-1-carbonyl)-1H-indol-2-yl]-(4-methanesulfonyl-piperazin-1-yl)-methanone,
[1-(3-chloro-phenyl)-5-(4-isopropyl-piperazine-1-carbonyl)-1H-indol-2-yl]-[4-(piperidine-1-sulfonyl)-piperazin-1-yl]-methanone,
(4-benzenesulfonyl-piperazin-1-yl)-[1-(3-chloro-phenyl)-5-(4-isopropyl-piperazine-1-carbonyl)-1H-indol-2-yl]-methanone,
[1-(2-chloro-pyridin-4-yl)-5-(4-isopropyl-piperazine-1-carbonyl)-1H-indol-2-yl]-[4-(piperidine-1-carbonyl)-piperazin-1-yl]-methanone,
4-[1-isopropyl-5-(4-isopropyl-[1,4]diazepane-1-carbonyl)-1H-indole-2-carbonyl]-piperazine-1-carboxylic acid ethyl ester,
[1-isopropyl-5-(4-isopropyl-[1,4]diazepane-1-carbonyl)-1H-indol-2-yl]-(4-methanesulfonyl-piperazin-1-yl)-methanone,
and any pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
